Oxybutynin chloride - ALZA

Drug Profile

Oxybutynin chloride - ALZA

Alternative Names: Ditropan XL; Lyrinel XL; oxybutynin; Oxybutynin - ALZA

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator ALZA Corporation
  • Developer ALZA Corporation; Aventis Pharmaceuticals; Bayer; Crescendo Pharmaceuticals; Sanofi
  • Class Antispasmodics; Carbocyclic acids; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Overactive bladder

Most Recent Events

  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 20 Oct 2003 A pharmacoeconomic study has been added to the Genitourinary disorders therapeutic trials section
  • 05 Aug 2003 A study has been added to the adverse events and Genitourinary disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top